Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts give Alnylam a consensus "Moderate Buy" (28 firms), with an average 12‑month price target of about $478 and a wide range of individual targets and ratings.
• Company announced a research collaboration with Tenaya to pursue cardiovascular RNAi targets — a deal that includes upfront/research funding and up to $1.13 billion in milestones — alongside reimbursement wins and trial progress that boost commercial visibility.
• Several insiders (including the CEO and EVPs) have recently sold shares — roughly 53,923 shares valued at ~$18.1M in the last 90 days — while the stock trades near $320 after a quarter that saw strong revenue growth but missed EPS and revenue estimates.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-eight ratings firms that are covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $477.9604.

A number of equities research analysts recently issued reports on the company. Barclays assumed coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They issued an "overweight" rating and a $527.00 target price on the stock. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a report on Thursday, January 15th. Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating for the company in a report on Friday, January 30th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 17th. Finally, Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a "buy" rating in a research report on Thursday, December 11th.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 1,775 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50. Following the completion of the transaction, the executive vice president directly owned 23,406 shares of the company's stock, valued at approximately $7,483,834.44. This represents a 7.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,598 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the transaction, the executive vice president directly owned 36,606 shares in the company, valued at $11,993,955.90. This trade represents a 4.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,923 shares of company stock valued at $18,072,087 in the last ninety days. Insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SHP Wealth Management acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $43,000. Reflection Asset Management acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $63,000. Wick Capital Partners LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $306,000. Alpine Global Management LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $820,000. Finally, Anchor Investment Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 19.8% in the fourth quarter. Anchor Investment Management LLC now owns 2,695 shares of the biopharmaceutical company's stock valued at $1,072,000 after buying an additional 446 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease; the deal includes upfront cash and research funding plus up to $1.13 billion in milestone payments, expanding Alnylam’s RNAi pipeline into a large disease area. Read More.
• Positive Sentiment: Coverage notes a reimbursement win and reported trial progress for Alnylam’s programs — improving near‑term commercial visibility for approved RNAi medicines and supporting revenue upside against current valuation. Read More.
• Positive Sentiment: Industry backdrop remains supportive: market reports project strong growth for orphan drugs, which underpins long‑term demand for Alnylam’s rare‑disease franchises. Read More.
• Neutral Sentiment: Short‑interest figures in recent reports show zero shares and a 0.0 days‑to‑cover — this appears to be a reporting glitch and is unlikely to represent a real change in short positioning.
• Neutral Sentiment: Analyst coverage remains mixed to favorable with a consensus “Moderate Buy” and a wide range of price targets; useful context for longer‑term expectations but not an immediate driver. Read More.
• Negative Sentiment: Significant clustered insider selling: CEO Yvonne Greenstreet reported selling ~6,799 shares (~$2.23M) and multiple EVPs sold 1.6k–2.2k shares each across March 2–3. These concurrent executive sales (disclosed in SEC filings and insider summaries) can create short‑term negative sentiment and add selling pressure despite insiders retaining large holdings. Read More. Read More.

Alnylam Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ:ALNY opened at $320.51 on Friday. The firm has a market cap of $42.51 billion, a price-to-earnings ratio of 187.43 and a beta of 0.36. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $495.55. The company's fifty day simple moving average is $353.84 and its 200 day simple moving average is $415.74. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals's revenue for the quarter was up 84.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.65) EPS. As a group, research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.